Sionna Secures $182M Series C Funding to Advance Novel Cystic Fibrosis Treatment Pipeline

- Sionna Therapeutics, a clinical-stage life sciences company focused on developing treatments for cystic fibrosis, announces a successful closure of a $182 million Series C financing.
- The oversubscribed funding round was led by Enavate Sciences, with contributions from Viking Global Investors, Perceptive Advisors, and existing investors like RA Capital, OrbiMed, TPG's The Rise Fund, and the Cystic Fibrosis Foundation.
- The funding supports the clinical development of Sionna's first-in-class small molecules aimed at correcting the protein defects related to the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
- Sionna's pipeline includes three NBD1 stabilizers (SION-638, SION-719, and SION-451) and one ICL4 inhibitor (SION-109), with multiple clinical trials planned for 2024.
- The company's lead candidate, SION-638, has identified doses that are generally safe and well-tolerated in a Phase 1 clinical trial, achieving target exposure at all doses.
- A Phase 1 clinical trial for SION-109 began in January 2024, targeting the interface between the ICL4 region and NBD1 of the CFTR protein.
- Sionna aims to have four compounds in clinical trials in 2024, with the goal of delivering best-in-class efficacy and reaching previously unachievable levels of long-term benefits for cystic fibrosis patients.

Sources:

- PR Newswire: Sionna's $182 million Series C financing for clinical push in cystic fibrosis treatment development
- First Word Pharma: Brief on Sionna securing $182 million for clinical push
- PR Newswire: SION-109 Phase 1 trial initiation
- PR Newswire: Sionna's Series C financing details
- Cystic Fibrosis News Today: Sionna's funding for small molecules to aid CFTR function
- Pharmaceutical Technology: Sionna's funding and clinical development plans